Reduced Risk of Hypoglycemia with Insulin Degludec Versus Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: A Meta-Analysis of 5 Randomized Begin Trials

Helena Rodbard; Stephen Gough; Wendy Lane; Lars Korsholm; Ditte-Marie Bretler; Yehuda Handelsman

doi:10.4158/ep13287.or

Reduced Risk of Hypoglycemia with Insulin Degludec Versus Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: A Meta-Analysis of 5 Randomized Begin Trials

Endocrine Practice ◽

10.4158/ep13287.or ◽

2014 ◽

Vol 20 (4) ◽

pp. 285-292 ◽

Cited By ~ 36

Author(s):

Helena Rodbard ◽

Stephen Gough ◽

Wendy Lane ◽

Lars Korsholm ◽

Ditte-Marie Bretler ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text

Reduced Risk of Hypoglycemia with Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes Requiring High Doses of Basal Insulin: Meta-Analysis of Five Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2012.07.399 ◽

2012 ◽

Vol 36 (5) ◽

pp. S57 ◽

Cited By ~ 2

Author(s):

Helena W. Rodbard ◽

Yehuda Handelsman ◽

Stephen Gough ◽

Jina Hahn ◽

Nathan Lassota ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis

Diabetes Therapy ◽

10.1007/s13300-019-0624-4 ◽

2019 ◽

Vol 10 (3) ◽

pp. 835-852 ◽

Cited By ~ 3

Author(s):

Wenchuan Zhou ◽

Jinxin Tao ◽

Xiaodong Zhou ◽

Hongxia Chen

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Meta Analysis ◽

Insulin Degludec ◽

Long Acting

Download Full-text

Reduced Risk of Nocturnal-Confirmed Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 1 Diabetes Requiring High Doses of Basal Insulin: a Meta-analysis of 2 Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2013.08.160 ◽

2013 ◽

Vol 37 ◽

pp. S54

Author(s):

Helena W. Rodbard ◽

Yehuda Handelsman ◽

Stephen C.L. Gough ◽

Todd M. Hobbs ◽

Lars Korsholm ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

High Doses ◽

Reduced Risk

Download Full-text

Reduced Risk of Hypoglycemia with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes and a BMI >30 kg/m2: A Meta-analysis of 5 Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2013.08.166 ◽

2013 ◽

Vol 37 ◽

pp. S56

Author(s):

Helena W. Rodbard ◽

Luigi F. Meneghini ◽

David L. Russell-Jones ◽

Rahul Kapur ◽

Lars Endahl ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

Reduced Risk

Download Full-text

Reduced Risk of Confirmed Hypoglycemia (Plasma Glucose <2.3 mmol/L) with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes: A Meta-analysis of 5 Randomized Trials

Canadian Journal of Diabetes ◽

10.1016/j.jcjd.2013.08.156 ◽

2013 ◽

Vol 37 ◽

pp. S53

Author(s):

Alan J. Garber ◽

Todd M. Hobbs ◽

Søren Rasmussen ◽

Jina Hahn ◽

Helena W. Rodbard

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Plasma Glucose ◽

Randomized Trials ◽

Meta Analysis ◽

Insulin Degludec ◽

Reduced Risk

Download Full-text

Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2017.1400011 ◽

2017 ◽

Vol 18 (17) ◽

pp. 1789-1798 ◽

Cited By ~ 14

Author(s):

Xiaoling Cai ◽

Xueying Gao ◽

Wenjia Yang ◽

Linong Ji

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Meta Analysis ◽

Insulin Degludec

Download Full-text

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

The Lancet ◽

10.1016/s0140-6736(10)62305-7 ◽

2011 ◽

Vol 377 (9769) ◽

pp. 924-931 ◽

Cited By ~ 89

Author(s):

Bernard Zinman ◽

Greg Fulcher ◽

Paturi V Rao ◽

Nihal Thomas ◽

Lars A Endahl ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Basal Insulin ◽

Insulin Degludec ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Long Acting

Download Full-text

Review for "Insulin glargine/lixisenatide fixed‐ratio combination ( iGlarLixi ) compared to premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis"

10.1111/dom.14148/v3/review2 ◽

2020 ◽

Author(s):

CHARLES KHOURI

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Insulin Glargine ◽

Bayesian Network ◽

Basal Insulin ◽

Meta Analysis ◽

Fixed Ratio ◽

Meal Time

Download Full-text

Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin

Primary Care Diabetes ◽

10.1016/j.pcd.2020.08.004 ◽

2021 ◽

Vol 15 (1) ◽

pp. 132-137

Author(s):

Anwar Ali Jammah

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Insulin Aspart ◽

Basal Insulin ◽

Indirect Comparison ◽

Insulin Degludec ◽

Efficacy And Safety ◽

Diabetes Patients

Download Full-text

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

BMJ Open ◽

10.1136/bmjopen-2015-009421 ◽

2016 ◽

Vol 6 (2) ◽

pp. e009421 ◽

Cited By ~ 35

Author(s):

Nick Freemantle ◽

Engels Chou ◽

Christian Frois ◽

Daisy Zhuo ◽

Walter Lehmacher ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Glargine ◽

Basal Insulin ◽

Meta Analysis ◽

Safety And Efficacy

Download Full-text